Optimal response to dimethyl fumarate is mediated by a reduction of Th1‐like Th17 cells after 3 months of treatment

AIM: Dimethyl fumarate (DMF) is one of the most promising therapies for relapsing‐remitting multiple sclerosis (RRMS) patients since it has shown immunomodulatory and neuroprotective effects. However, a percentage of RRMS patients do not exhibit an optimal response to DMF. The objective of this stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Mansilla, María José, Navarro‐Barriuso, Juan, Presas‐Rodríguez, Silvia, Teniente‐Serra, Aina, Quirant‐Sánchez, Bibiana, Ramo‐Tello, Cristina, Martínez‐Cáceres, Eva María
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698982/
https://www.ncbi.nlm.nih.gov/pubmed/31066225
http://dx.doi.org/10.1111/cns.13142

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698982/
https://www.ncbi.nlm.nih.gov/pubmed/31066225
http://dx.doi.org/10.1111/cns.13142

Ejemplares similares